Late last month, Japan’s Ministry of Health, Labour, and Welfare (MHLW) approved AstraZeneca’s (NASDAQ:AZN) diabetes and heart failure drug, Forxiga (known as Farxiga in the United States), to treat patients with chronic kidney disease, or CKD. This made…

Click here to view the original article.